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S348 Poster Session IIRisk factors for outcomeswere analyzed and includedHematopoi-
etic cell transplantation comorbidity index (HCT-CI) score (Sorror,
Blood 2005), relapse risk score (Kahl, Blood 2007) and risk stratifica-
tion by age groups.110 patients (69%) had low or standard relapse
risk score while 49 (31%) had high score. 26 patients (16%) had
HCT- CI score of 0, 48 patients (30%) had score of 1-2, 48(30%)
had score of 3-4 and 32 (20%) had score of 5 or above.
Increasing HCT-CI score had a significant impact on OS in both
univariate and multivariate analysis (p\0.05). HCT-CI of 1-2, 3-4
and 5 plus was prognostic for OS (HR 2.6, 2.9 and 3.6; p 5 0.006,
0.005 and 0.001 respectively).For PFS, high relapse risk score was
prognostic (HR 7.8, p 5 0.001) but increasing HCT-CI score lost
significance.Risk stratification by age groups (60-65, 66-70 and 70
plus) did not show any prognostic implication on either PFS or OS.
Our results support the use of RIC HCT as a potentially curative
treatmentmodality for elderly patients, and as well support the prog-
nostic value ofHCT-CI score. Elderly patients with high scores (.5)
may not benefit fromundergoingHCTevenwithRIC orNMHCT.
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BLAST PERCENTAGE PRIOR TO TRANSPLANTATION IS THE STRONGEST
PREDICTIVE FACTOR FOR SURVIVAL AFTER ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT (HSCT) IN PATIENTS WITH MYELODYS-
PLASTIC SYNDROME (MDS)
Jimenez, A.M.1, Rich, E.S.1, Nathan, S.1, Maciejewski, J.1,
Shammo, J.M.1, Katz, D.1, Braun, E.1, Hashmi, S.2, Fung, H.C.1
1Rush University Medical Center, Chicago, IL; 2West Suburban Hospital,
Chicago, IL
Background: Allogeneic hematopoietic stem-cell transplantation
(HSCT) is the only curative treatment for patients (pts) with myelo-
dysplastic syndromes (MDS) or secondary acute myeloid leukemia
(sAML)with long-term survival rates between 25% and 70%.Disease
stage at timeof transplantationhasbeenstrongly correlatedwith trans-
plant outcomes; current data suggests that achieving a low pre-trans-
plant tumor burden is critical for a successful allograft. We sought
to retrospectively identify the relationship between pre-transplant
blast percentage and clinical outcomes following HSCT inMDS pts.
Methods: We conducted a retrospective review of pts with MDS
who received an allogeneic HSCT in our institution from 1998 to
2010. We previously reported the impact of clinical characteristics
and treatment on outcomes in this patient population.We quantified
the pre-transplant marrow burden on all pts with available pathol-
ogy. Bone marrow biopsy was performed prior to allogeneic
HSCT and pts’ blast burden was quantified as low or high on the ba-
sis of blast percentage (\5% or $5% respectively).
Results: 35 MDS pts were transplanted at our institution between
1998 and 2010. Median age was 51 years (range: 24-66); male to fe-
male ratio 1:1; matched related donor 46% (n5 16); matched unre-
lated donor 54% (n 5 19). Cytogenetic risk group by IPSS: good,
40% (n5 14), intermediate, 37% (n5 13), poor, 23% (n5 8). Graft
source was mobilized peripheral blood in 80% (n 5 28) and bone
marrow in 20% of pts (n5 7). Information on marrow blast percent-
age prior to transplant was available for 32 pts; survival was 53% at 1
year and 40% at 2 years in this group. Survival at one year was supe-
rior for pts with low blast burden compared to those with$5%blasts
(68% vs. 30%, respectively p: 0.036). Among the 17 pts alive at 1
year, 77% had low blast burden (vs. only 40% in those pts who didn’t
survive past day +365). Blast percentage prior to transplant also pre-
dicted for survival on multivariate analysis (p: 0.042).
Conclusions: Our retrospective analysis identified blast percentage
as an independent predictor of clinical outcomes in MDS pts under-
going HSCT. Our results are consistent with the current literature.
Prospective evaluation of multiple clinical variables in a larger patient
population is warranted to better characterize prognostic factors. The
role of cytoreductive therapy prior to transplant in order to achieve
a low blast burden should be further evaluated in this setting.
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THE EFFECT OF KIRS EXPRESSION PROFILE IN DONOR/RECIPIENT
PAIRS IN HLA IDENTICAL SIBLING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Tang, X., Wei, X., Feng, Y., Zhu, Z., He, J., Xu, Y. First Affiliated Hos-
pital of Soochow University, Jiangsu Institute of Hematology, Suzhou,
Jiangsu, ChinaObjective: We investigated the distribution characteristics of KIRs
expression profile in donor/recipient pairs with acute leukemia (AL)
receiving HLA-identical sibling hematopoietic stem cell transplan-
tation (sib-HSCT). We further explored the effect of KIRs expres-
sion profile in donor/recipient pairs on clinical outcome.
Methods: The genotypes of donor/recipient KIRs were determi-
nated by polymerase chain reaction- sequence specific primer
(PCR-SSP) for 80 pairs of donor/recipient receiving HLA-identical
sibling hematopoietic stem cell transplantation.
Results: 1. In 80 pairs of donor/recipient: (i) the KIRs were com-
pletely identical in 57.5% of donor/recipient pairs; (ii) the donors’
KIRs contained the recipients’ in 13.75% pairs; (iii) the recipients’
KIRs contained the donors’ in 17.5% of pairs; (iv) the KIRs were
completely different in 11.25% pairs. The graft versus host (GVH)
direction KIR-matched group was 75%. The percentage of group
donor B/X and group donor A/A was 50%, respectively. 2.Compar-
ing the patients fromGVH direction KIR-matched and mismatched
group, the incidence of acute (a) GVHD was 60% and 30%, respec-
tively (p5 0.0222), and 2-year OS was 62.96% and 94.12%, respec-
tively (p 5 0.0492). Particularly, grade III-IV aGVHD rate of
KIR-matched group was higher than that of non-KIR matched
group(15% vs 0%). 3. Donor B/X group had a higher 2-year OS
and 2-year relapse-free survival (RFS) compared with donor A/A
group (89.23% vs 49.57%, p 5 0.0159, and 90% vs 59.71%, p 5
0.0239, respectively). Patients with three or less aKIRs had a lower
2-year OS (58.9% vs 92.44%, p 5 0.0338) and a lower RFS
(65.14% vs 92.59%, p 5 0.0398), compared with patients with
more aKIR.
Conclusions: Donor KIR genotype appears to have a direct impact
on aGVHD, OS and RFS. Therefore, donor KIR genotype should
be evaluated as an outcome predictor of the HLA-identical sib-
HSCT.390
COMPARABLE SURVIVAL AFTER UNRELATED AND RELATED ALLOGE-
NEIC STEM CELL TRANSPLANTATION PERFORMED AT COMMUNITY CAN-
CER CENTERS
Khaled, Y., Solh, M., Zehngebot, L., Zakari, A., Reynolds, R., Castillo, R.,
Alemany, C., Reddy, V. Florida Cancer Institute, Orlando, FL
The outcomes after unrelated donor hematopoietic stem cell
transplantation (MUD HCT) have improved over the past decade
with survival equivalent to related donors (RD) HCT. Although
MUD HCT is becoming more available in community cancer cen-
ters, there is very limited literature available about the outcomes of
MUDHCT outside the academic setting. To study the above ques-
tion, we performed a retrospective analysis of the outcomes of 56
consecutive patients that underwent HCT (30 MUD, 26 RD) be-
tween August 2007 and July 2010 at our community cancer center.
All patients had a minimum follow up of one year post HCT. There
was no statistical difference between MUD and RD recipients
(Table 1). Conditioning regimens used were Fludarabine/Melpha-
lan in 13 patients (3 MUD & 10 RD), Busulfan based in 28 patients
(19 MUD & 9 RD), Fludarabine/TBI in 10 patients (5 MUD & 5
RD), Cytoxan/TBI in 2 patients (1 MUD & 1 RD) and other in 3
patients (2 MUD & 1 RD). Graft versus Host Disease (GVHD)
prophylaxis regimens used were Tacrolimus/Methotrexate in FIC
HCT recipients and Cyclosporine/Mycophenolate mofetil in
RIC/NMA HCT recipients. MUD HCT recipients received addi-
tional Thymoglobulin (4.5 mg/Kg). Median time to neutrophils en-
graftment was 14 days for RD and 13 days for MUD. The
cumulative incidence of acute GVHD (grade I-IV) was 60% for
MUD and 54% for RD. The cumulative incidence of chronic
GVHD was comparable between both groups of 63% and 72%
for MUD and RD respectively.
With median duration follow up of 2 years, there was no statistical
difference in overall survival (OS) at one and 2 years of 57% and 40%
for MUD recipients versus 65% and 54% for RD recipients respec-
tively (p 5 0.48). Similarly, disease free survival (DFS) at 1 and 2
years was 50% and 36% versus 50% and 22% for MUD and RD re-
cipients respectively (p5 0.24). There were more relapses in RD re-
cipients with cumulative incidence of 34% and 59% at 1 and 2 years
respectively compared to 23% at 1 and 2 years in MUD recipients.
Non relapse mortality (NRM) at day 100 was 10% and 8% for
Poster Session II S349MUDand RD recipients; respectively. MUD recipients had a higher
cumulative incidence of non- relapse mortality at 2 years of 34%
compared to 19% for RD recipients.
Conclusions:Outcomes afterMUDHCTwhen performed at com-
munity cancer centers were not inferior to outcomes after RDHCT.
It seems feasible to perform MUD HCT at community cancer cen-
ters with outcomes comparable to published literature.Mud (%) RD (%) p
Number 30 26
Median Age (Range) 55.86 (23-71) 53.8 (35-73) 0.18
Gender (F/M), % (10/30), 33.3% (13/26), 50% 0.32
Median CD 34 cell
dose (Range)
7.18 (1.89-11.35) 7.04 (2.87-10.4) 0.16
Diagnosis (Acute leukemia
Vs Others)
0.83
ALL 2 ( 7%) 7 (27%)
AML/MDS 19 (63%) 11 (42%)
Multiple Myeloma 0 3 (11%)
CLL/T-PLL 1/1 (7%) 1/1 (8%)
HD/NHL 1/2 (10%) 1/1 (8%)
MF 1 (3%) 1 (4%)
SAA 2 (7%) 0
CML 1 (3%) 0
Status at Transplant 0.21
CR1 13 (43%) 7 (27%)
CR2 or beyond 6 (20%) 3 (11.5%)
PR 2 (7%) 3 (11.5%)
Persistent/Progressive
Disease
6/2 (27%) 5/5 (38.5%)
Primary Refractory 1 (3%) 3 (11.5%)
Cytogenetics 0.86
Normal Cytogenetics 12 (40%) 12 (46%)
High Risk Cytogenetics 18 (60%) 14 (54%)
Prior Transplant
Autologous 1 5
Allogeneic 2 1
Co-Morbidity Index 0.84
CCI 1-2 10 (33%) 8 (31%)
CCI 3 or more 20 (67%) 18 (69%)
Distance From Transplant
Center
0.43
Median 21.2 miles 23.1 miles
Range 5-131 miles 4.9-130 miles
Conditioning Regimens 0.39
RIC/NMA 15 (50%) 17 (65%)
FIC 15 (50%) 9 (35%)
MF indicates myelofibrosis; RIC, reduced intensity conditioning; FIC, full
intensity conditioning; NMA, non-myeloablative.391
HAPLOIDENTICAL TRANSPLANT WITH HIGH DOSE OF UNMANIPULATED
CD34, IN VIVO T CELL DEPLETION WITH ALEMTUZUMAB AND RIC REG-
IMEN. GOOD ENGRAFTMENT RATE, LOW GVHD INCIDENCE AND EN-
COURAGING SURVIVAL. SINGLE CENTER EXPERIENCE IN COLOMBIA
Karduss, A.J., Coll, Y., Alejo, J., Rodolfo, G.L., Pedro, R., Hilda, D.,
Hurtado, L. Instituto de Cancerologia- Clinica las Americas, Medellin,
Colombia
For a successful haploidentical transplant is necessary to overcome
the HLA barrier. We present our experience using high dose of un-
manipulated CD34, in vivo T cell depletion and a RIC regimen.
After a signed inform consent seventeen patients received 20 trans-
plants (3 ptes. underwent a second haplo transplant after engraft-
ment failure of the first). 9 were women, median age was 17.3
years (7-36), 40% were under sixteen. 5 patients had high risk
AML CR1 or CR 2; 3 had high risk ALL CR1 or CR3; 5 heavily
transfused Fanconi anemia,1 aplastic anemia,1 myelofibrosis, 1den-
dritic cell leukemia CR2, 1 hemophagocytic linphohistiocytosis.Two patients received the haplo transplant after an unsuccessful
cord blood transplant. The donors were 16 mothers, 3 siblings and
1 father. 80% had 3 out of 6 match.
The conditioning was cyclophosphamide 2000 mgs/m2, fludara-
bine 120 mgs/m2 +/- thiothepa 5 mgs/kg. In 11 procedures TBI
200-400 Cgy was added. In vivo T cell depletion was done with
Alemtuzumab 0.2 mg/kg/day from day -4 to cero. All patients re-
ceived unmanipulated peripheral blood CD34 obtained by apheresis
(median 12 mill/kg) in 2 cases bone marrow was added. The GVHD
prophylaxis was accomplished with CyA for 180 days and MMF for
30. Filgrastimwas administered fromD+6 until neutrophil recovery.
Neutrophil engraftment occurred at median of 11 days (9-14) in
82% of the patients after first transplant and in 100% after the sec-
ond, 1 patient had a secondary graft failure. The incidence of acute
GVHDGI-II was 25%, there were no cases of GIII-IV. One patient
had aGVHDGIII after DLI, chronic GVHDwas presented in 40%
of the patients, in all cases limited, and in 50% of them treated with
only topical medication.
The 100 days mortality was 17.64 % and with a median follow up
of 16 months (1-38) the overall survival was 53.5%.
Conclusion:The strategy of use high dose of unmanipulated CD34,
in vivo T cell depletion and a RIC preparative regimen produce a re-
liable engraftment, low incidence of GVHD, low day 100 mortality
and good overall survival in this high risk group. It deserve more
studies.392
EARLY HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ALL PA-
TIENTS AFTER REDUCED INDUCTION CHEMOTHERAPY
Ghavamzadeh, A., Alimoghaddam, K., Pourkhani, H., Jahani, M.,
Mousavi, S.A., Bahar, B., Iravani, M., Jalili, M., Derakhshandeh, R.,
Jalali, A. Tehran University of Medical Sciences, Tehran, Islamic Republic
of Iran
Hematopoietic stem cell transplantation (HSCT) is only curable
treatment in ALL patients. However, the efficacy of induction, con-
solidation chemotherapy and early hematopoietic stem cell trans-
plantation remain unclear.
Therefore, at our center, patients with newly diagnosed ALL,
are randomly divided into 2 arms from 2008 to 2011. Patients in
the study arm received reduced induction chemotherapy (vincris-
tine 1 mg/m2 every week for 4 weeks plus dexamethasone 24mg/
d for 28 days) and undergone early HSCT after disease stabilized
within 15-30 days without intention of achieving complete remis-
sion (CR). The control arm received conventional chemotherapy
followed by HSCT. Both arms received busulfan (4mg/kg for 4
days) plus cyclophosphamide (60mg/kg for 2 days) as a condition-
ing regimen. Here, we compare the efficacy of these two kinds of
treatment.
A total of 90 patients enrolled in the study. Eighteen patients al-
located to the study arm and 72 others allocated to the control arm.
The median age was 21.5 years (range: 16-33) in the study arm and
22 years (range: 3-49) in the control arm. All patients underwent
Allogeneic HSCT with peripheral blood source. The median wait-
ing time from diagnosis to HSCT was 217 days (range: 45-708) in
the control arm. In the study arm, 14 patients (78%) were in CR1.
The median follow-up time was 15.5 months (range: 2-32) in the
study arm and 12.5 months (range: 1-39) in the control arm. Re-
lapse occurred in 2 (11.1%) and 6 (8.3%) patients of the study
and the control arms, respectively. Five patients (27.7%) of the
study arm and 10 patients (13.5%) of the control arm were died.
The causes of death were GVHD and sepsis in 3 (60%) patients
and relapse in 2 (40%) patient in the study arm. The causes of
death were GVHD in 6 (60%) patients and relapse in 4 (40%) pa-
tients in the control arm. One-year overall survival was 81.9% (SE:
9.5%) and 84.8% (SE: 4.8%) in study and control arms, respec-
tively (p 5 0.221). One-year disease-free survival was 81.9% (SE:
9.5%) and 82.4% (SE: 4.9%) in study and control group, respec-
tively (p 5 0.532).
Reduced induction followed by early transplantation without con-
solidation reveals no significant statistical different outcome com-
pared with routine treatment. This result might be due to small
size of patients and short time of follow-up. A study with more cases
and long time follow-up is recommended.
